Long-term outcomes of Japanese patients with deferral of coronary intervention based on fractional flow reserve in multicenter registry

Conditions

stable angina pectoris and unstable angina pectoris

Ryosuke Itakura, Shoichi Kuramitsu, Jun Kikuchi, Yoshiaki Kawase, Takuya Mizukami et al. (30 authors)

Journal of the American Heart Association2023-10-071 citations

10.1161/jaha.123.030886

Five-Year Outcomes After Fractional Flow Reserve–Based Deferral of Revascularization in Chronic Coronary Syndrome: Final Results From the J-CONFIRM Registry

Shoichi Kuramitsu, Hitoshi Matsuo, Tomohiro Shinozaki, Kazunori Horie, Hiroaki Takashima et al. (26 authors)

Circulation Cardiovascular Interventions2022-02-0126 citations

10.1161/circinterventions.121.011387

Thrombotic Risk and Cardiovascular Events in Patients With Revascularization Deferral After Fractional Flow Reserve Assessment.

Shiono Y, Kuramitsu S, Matsuo H, Horie K, Takashima H, Terai H, Kikuta Y, Ishihara T, Saigusa T, Sakamoto T, Suematsu N, Asano T, Tsujita K, Masamura K, Doijiri T, Toyota F, Ogita M, Kurita T, Matsuo A, Harada K, Yaginuma K, Sonoda S, Tanaka A, Yokoi H, Tanaka N, J-CONFIRM Registry Investigators.

2022-02-015 citations

10.1016/j.jcin.2021.11.020

Two-Year Outcomes After Deferral of Revascularization Based on Fractional Flow Reserve

Shoichi Kuramitsu, Hitoshi Matsuo, Tomohiro Shinozaki, Kazunori Horie, Hiroaki Takashima et al. (18 authors)

Circulation Cardiovascular Interventions2019-12-3040 citations

10.1161/circinterventions.119.008355

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (I) Patients were clinically suspected of angina pectoris and underwent coronary angiography. (II) Coronary angiography showed more than 50% diameter stenosis by visual estimation and FFR examination was done. (III) Patients fulfilled (I),(II) and any one of the following criteria: 1) defered PCI based on FFR >0.80; 2) underwent PCI regardless of FFR >0.80; and 3) defered PCI regardless of FFR &#8804;0.80.

Exclusion criteria

Exclusion criteria: 1) ST and non-ST elevated myocardial infarction 2) emergent percutaneous coronary intervention 3) cardiogenic shock (Killip class IV) 4) lesion with chronic total occlusion 5) limited life expectancy due to cancer 6) inability to give informed consent

Design outcomes

Primary

Measure	Time frame
Primary outcome is target vessel failure (TVF) at 2-year. TVFis defined as a composite of cardiac death related to target vessel, myocardial infarction, and clinically driven target vessel revascularization.	—

Secondary

Measure	Time frame
1) Annual TVF at 1, 2, 3, 4, and 5 years 2) Annual Major Adverse Cardiac and Cerebrovascular Events (MACCE) and in-stent thrombosis at 1, 2, 3, 4, and 5 years 3) Annual MACCE according to success of coronary risk factor management control via pharmacotherapy at 1, 2, 3, 4, and 5 years 4) Annual MACCE for dialysis cases at 1, 2, 3, 4, and 5 years 5) Annual MACCE for stented and non-stent (de novo) lesions at 1, 2, 3, 4, and 5 years 6) Annual MACCE for diabetes and non-diabetes cases at 1, 2, 3, 4, and 5 years 7) Factorial analysis of patient background of MACCE event group and non-event group 8) Sub-group analysis of Annual MACCE rates for PCI group, DEFER group and Non-PCI group at 1, 2, 3, 4, and 5 years 9) Annual MACCE sub-grouped by iFR measurement (optional measurement item) at 1, 2, 3, 4, and 5 years *MACCE is defined as all mortality, non-fatal MI, stroke, and Clinically driven PCI or CABG.	—

Measure

Time frame

1) Annual TVF at 1, 2, 3, 4, and 5 years 2) Annual Major Adverse Cardiac and Cerebrovascular Events (MACCE) and in-stent thrombosis at 1, 2, 3, 4, and 5 years 3) Annual MACCE according to success of coronary risk factor management control via pharmacotherapy at 1, 2, 3, 4, and 5 years 4) Annual MACCE for dialysis cases at 1, 2, 3, 4, and 5 years 5) Annual MACCE for stented and non-stent (de novo) lesions at 1, 2, 3, 4, and 5 years 6) Annual MACCE for diabetes and non-diabetes cases at 1, 2, 3, 4, and 5 years 7) Factorial analysis of patient background of MACCE event group and non-event group 8) Sub-group analysis of Annual MACCE rates for PCI group, DEFER group and Non-PCI group at 1, 2, 3, 4, and 5 years 9) Annual MACCE sub-grouped by iFR measurement (optional measurement item) at 1, 2, 3, 4, and 5 years *MACCE is defined as all mortality, non-fatal MI, stroke, and Clinically driven PCI or CABG.

—

Countries

Japan

Contacts

Public ContactShoichi Kuramitsu

Kokura Memorial Hospital Cardiology

kuramitsu@circulation.jp093-511-2000

Outcome results